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Abstract While the global HIV incidence dropped about
20 % in the past 10 years, HIV incidences among people
who inject drugs (PWID) in Asia and Europe continue to
increase and to account for high proportions of new HIV
infections among PWID globally. Great changes have been
observed in this region, such as progressing from rejection
to acceptance of harm reduction strategies in Asian coun-
tries, but no such change has occurred in Eastern European
countries. China has quickly scaled up harm reduction ac-
tivities nationwide, resulting in the decline of HIV incidence
and HIV prevalence among PWID since 2006. However,
insufficient scaling up of harm reduction programs in other
countries has failed to slow down their HIV epidemics. In
Eastern European countries where the spread of HIV among
PWID is the most severe, only about 15 % of funding for
harm reduction programs are from domestic sources. Strong
political and financial commitment from countries in this
region is urgently needed to quickly scale up evidence-
based harm reduction strategies in order to prevent the
HIV epidemic from spreading rapidly from PWID to the
heterosexual general population.
Keywords Injecting drug use . HIV/AIDS . Harm
reduction . Antiretroviral treatment . Asia . Eastern Europe .
People who inject drugs (PWID) . HIV infection among
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Introduction
Globally, the three most widely used illicit drugs re-
main cannabis (global prevalence ranging from 2.6 to
5.0 %), amphetamine-type stimulants (ATS) (0.3-
1.2 %) and opioids (i.e., opium, heroin, and prescrip-
tion pain relievers, 0.6-0.8 %). Both ATS and opioids
continue to be the dominant drug type accounting for
treatment demand in Asia and Europe [1]. The most
devastating harm is often observed among opioids
users. The major consequences to the opioids user
include overdose-related death and unsafe injecting be-
havior causing infection with human immunodeficiency
virus (HIV) and hepatitis C virus (HCV), both of
which contribute to significantly higher mortality rates
in this population [2, 3].
The recently released 2012 UNAIDS global report
noted extraordinary progress in combating the health
challenges of the global HIV/AIDS epidemic, particularly
in bringing HIV programs to scale [4••]. However, in
contrast to decreasing numbers of new HIV infections
worldwide, the incidence of HIV in Eastern Europe and
Central Asia has been on the rise since the late 2000s
[4••, 5]. In many Eastern European and Asian countries,
national HIV epidemics are primarily driven by injecting
drug use-related transmission with further transmission to
their sexual partners [4••, 6, 7]. This article will review
the current HIV epidemiology, response, and challenges
in the context of injecting drug use in Eastern Europe and
Asia.
Trends of Dual Epidemics of Injecting Drug Use
and HIV Infection
Outside of sub-Saharan Africa, the regions most heavily
affected by the HIV epidemic are the Caribbean, Eastern
Europe, and Central Asia, where HIV infection prevalence
rates stood at 1.0 % in 2011 [4••]. In Eastern Europe and
Asia, there were an estimated 6.23 million people living
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with HIV/AIDS (PLWHA) in 2011, an increase of 1.17
million since 2001 [4••]. Of the nine countries where HIV
incidence increased over 25 % between 2001 and 2011, six
are in Asia (Bangladesh, Indonesia, Kazakhstan,
Kyrgyzstan, Philippines, and Sri Lanka) and two are in
Eastern Europe (Georgia and the Republic of Moldova)
[4••].
Due to the high efficiency of HIV transmission through
contaminated injecting drug equipment, people who inject
drugs (PWID) are among the population groups most affect-
ed by HIV infection. Globally, there are an estimated 16
million people who inject drugs, of whom 3 million are
living with HIV [1, 6]. Reported data suggests that PWID
experience HIV infection prevalence that are at least 22
times higher than the general population [4••]. Initially (up
to the1990s), outbreaks of HIV in PWID were limited to
North and South America and Europe. However, since the
early 2000s, HIV has spread rapidly among PWID in
Eastern Europe and in many countries of South, Central
and South-East Asia [8]. A large PWID population is cause
for concern due to the potential for HIV transmission to the
general population through risky sexual behaviors and
mother-to-child transmission.
In China and Russia, the countries with the first and third
largest PWID populations, the estimated HIV prevalence
among PWID is 12.3 % and 37.2 %, respectively [6]. Of
the 14 reporting countries with estimated mid-range HIV
prevalence among PWID over 20 %, nine are in Eastern
Europe or Asia: Estonia (72.1 %), Russia (37.2 %), Ukraine
(41.8 %), Myanmar (42.6 %), Cambodia (22.8 %),
Indonesia (42.5 %), Thailand (42.5 %), Vietnam (33.9 %),
and Nepal (41.4 %) [6]. Outbreaks in other countries have
similarly high HIV prevalence existing among PWID in
concentrated areas, such as Dushanbe, Tajikistan (24 %),
Karaganda, Kazakhstan (19 %), and Chennai, India (25 %)
[9, 10].
Five Eastern European and Asian countries (Russia,
Ukraine, China, Vietnam, and Malaysia) account for 47 %
of all HIV infections in PWID in low- and middle-income
countries [6, 11]. Russia has one of the fastest growing HIV
epidemics in the world, which is heavily concentrated (~80%)
in its PWID population estimated at 1.8 million [6, 12, 13].
National annual prevalence estimates for the use of opioids
and heroin are 2.3 % and 1.4 %, respectively [1]. A high
overlap between the female PWID and sex worker
populations has been noted [14]. Studies of PWID in St.
Petersburg found that the HIV epidemic was spreading at an
incidence rate of 14.1/100 person-years (95 % confidence
interval: 10.7–17.6) [15] and that half of self-reported HIV
discordant couples reported engaging in unprotected sex [16].
Ukraine has the highest HIV prevalence in Europe at
1.63 %, followed by Estonia at 1.3 % [17, 18]. Ukrainian
cities reported an explosive rise of HIV infections among
their PWID populations during the mid-1990s [19].
Estimates of the PWID population range from 230,000 to
360,000 [20]. Frequent police harassment and beatings have
been correlated with a higher likelihood of sharing needles
and other possibly contaminated injection equipment [19].
Other barriers to control of drug use include fear of stigma-
tization, discrimination, and limited knowledge of HIV risk
behaviors [20, 21].
In Asia, national HIV epidemics in China, Malaysia, and
Vietnam have been driven by injecting drug use [8]. Due to
the large population sizes of many Asian countries, relative-
ly low HIV prevalence rates still represent infections num-
bering in the millions. In 2011, 28.4 % of China’s estimated
780,000 HIV/AIDS infections were transmitted through
injecting drug use [22]. In Vietnam and Malaysia, 65 %
and 67 % of reported HIV infections were among PWID,
respectively [23, 24].
Recently there has been a trend among youth in China
and the countries of Southeast Asia toward use of non-
injecting and amphetamine type drugs [25]. While this re-
duces the risk of transmission through sharing of needles it
increases the risk of sexual transmission among users.
Control of these drug users is difficult because users of these
recreational non-injecting drugs are less likely to come to
the attention of the public health and security agencies.
There has been an increasing trend toward increasing injec-
tion drug use by women in China and Southeast Asia. Many of
these women resort to commercial sex to support their drug
habit. Further, wives of drug users are at increased risk of HIV
infection and of transmitting their infection to their offspring.
Russia and the Ukraine have made progress in decreasing
perinatal transmission but the outreach efforts to women in
these two countries and other affected countries have not been
successful in reaching female drug users [17, 26].
Harm Reduction Policy and Implementation
In the last decade, the countries of Eastern Europe and Asia
have experienced gradual shifts toward political acceptance
and implementation of HIV prevention and harm reduction
services, often through civil society advocacy [8, 23, 24, 27,
28]. Harm reduction activities include opioid substitution
treatment (OST) (e.g., methadone, buprenorphine) and clean
needle and syringe exchange programs (NSPs). A substan-
tial body of research supports the success of HIV prevention
through substitution treatment and NSPs for PWID [29–31,
32•, 33••, 34]. OST and NSPs have shown to be cost-
effective and cost-saving, even in resource-poor settings,
although worldwide coverage remains low [31, 34, 35].
However, it is unclear what proportion of the drug using
population will be willing to use OST. Further, drop out
rates for OST programs have been as high as 50 %. The
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success of OST programs is dependent on achieving high
staff morale and the provision of adequate counseling [36].
Studies in China have underscored the need to locate OST
programs where the drug users are [37, 38]. This is a
particular challenge in China, where many of the drug users
are located in remote, mountainous areas. NSP programs
have been shown to be effective but are dependent on
achieving a high enough coverage rate to significantly re-
duce the number of HIV-infected syringes and needles in the
target community. Although OST and NSP are gradually
being implemented in many of the countries with serious
drug problems, coverage has yet been insufficient to signif-
icantly reduce the spread of HIV among PWID [4••].
Contact with criminal justice systems remains a critical
challenge. A review of data from Eastern Europe and
Central Asia noted that between half and three-quarters of
PWID have experienced arrest [39•]. In Asia, confinement
of PWID in compulsory detention centers remains a com-
mon practice, despite concerns about effectiveness, lack of
access to HIV treatment, and human rights violations [23,
40, 41]. Within 6 months of release, the majority of the
detainees resume use of drugs. The compulsory treatment
centers are often more concerned with punishment and
getting drug users off the streets.
In Eastern Europe, overall coverage of harm reduction
services is low. OST is not available in Russia, Armenia,
Tajikistan, Turkmenistan, and Uzbekistan, where there is
immense political resistance to OST despite evidence
supporting its efficacy [27, 31, 42]. The situation in Russia
is particularly concerning, due to its large PWID population,
high HIV prevalence, the illegality of OST, brutal police
practices, and the low coverage of NSP [31, 43].
However, there are encouraging developments in Asia.
Both China and Vietnam are reducing the number of com-
pulsory detention centers and placing more emphasis on
rehabilitation. China, has established over 900 NSP sites
issuing a total of more than 12 million clean needles and
syringes each year and has opened 738 methadone treatment
centers [22]. A program in Vietnam funded by the UK
Department for International Development and the World
Bank will provide harm reduction services in 40 provinces
[44]. Malaysia, which has primarily relied on a punitive
response to illicit drug use, implemented a pilot OST pro-
gram in 2003 and a pilot NSP programs in 2006 [24].
Some countries in Asia have observed concrete results
for their harm reduction efforts. In China, the HIV preva-
lence among registered PWID fell from 9.3 % in 2009 to
6.4 % in 2011 [22]. While the estimated absolute numbers of
HIV-infected PWID has remained constant, the prevalence
of HIV among PWID in methadone maintenance treatment
has dropped from 1 % in 2006 to 0.2 % in 2012 (Wu Z,
conference presentation, 2012). Of note, Chinese PWID
engaged in both methadone maintenance treatment and
ART experienced lower 6- and 12-month mortality rates of
6.6 and 3.7 per 100 person-years, compared to 16.9 and 7.4
per 100 person-years for PWID engaged only in ART [45].
Hammet TM et al.’s long-term cross-border study in
Vietnam and China found that a package of peer outreach
and NSP interventions were correlated with significant de-
clines in HIV prevalence among PWID, HIV incidence
among new injectors, and drug-related risk behaviors
[32•]. Estimates based on BED capture-enzyme immunoas-
say testing revealed reductions in HIV incidence persisting
through 96 months [32•].
Antiretroviral Therapy for HIV-Infected PWID
Antiretroviral therapy (ART) has been shown to dramatical-
ly reduce HIV and AIDS-related morbidity and mortality as
well as HIV transmission [46–50]. Optimizing the linkage
between identification, care engagement, and treatment re-
tention is necessary for carrying out the “Treatment as
Prevention” strategy. A history of injecting drug use is a
risk factor for delays or denial in receiving ART, ART
initiation at advanced disease stage, problematic adherence,
and higher risk of death [11, 51, 52].
PWID in Eastern Europe and Asia have poor access to
ART [31, 53]. Alarmingly, in Eastern Europe, many of the
countries with the largest populations of HIV-infected PWID
and the highest number of new diagnoses also have the lowest
levels of ART and harm reduction services [39•, 53].
Adequate ART coverage to slow the epidemic is, of course,
dependent on reaching the majority of HIV-infected individ-
uals. This goal is particularly challenging for targeting
injecting drug users because they are a largely hidden popu-
lation who are reluctant to be identified, especially in central
Asia, Eastern Europe and many of the countries of Southeast
Asia. This problem underscores the need for public health
programs targeting injection drug users to gain the coopera-
tion of the security agencies in these countries.
Overall, the limited available data on national ART access
rates among PWID suggest that HIV treatment coverage is
very low [31]. In Russia, Pakistan, and Uzbekistan, it is
estimated that the number of IDUs receiving ART relative to
the estimated number of PWID is less than one recipient per
100 HIV-infected PWID [31]. In Estonia, where the estimated
HIV prevalence among PWID is 72.1 %, only 5-12% of HIV-
infected PWID reported current engagement on ART [18]. In
China, from 2002 to 2009, PWID comprised 15.5 % of
patients in the free national ART program despite accounting
for over a quarter of all reported infections [54]. Notably,
Chinese ART patients who were infected through injecting
drug use were more likely to have higher baseline CD4 cell
counts than patients who were infected through sexual trans-
mission or other routes [55, 56].
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Near universal HIV testing is essential for controlling the
epidemic. In an UNAIDS 2012 report, among 17 countries
which reported HIV testing coverage, the coverage among
injecting drug users was less than 25 %, nine of these
countries were in Asia and two in Eastern Europe. Clearly,
HIV testing of drug users must be increased, especially in
Asia and Eastern Europe which have among the lowest
testing rates [4••].
Challenges Addressing Injecting Drug Use
There are tremendous coverage and resource gaps in ad-
dressing injecting drug users in Eastern Europe and Asia.
There are critical tensions between drug policy, human
rights, and public health policies, resulting in environments
where access to care services are discouraged or disrupted
[44, 57, 58]. Drug use and HIV/AIDS have both been
politicized creating a formidable barrier to implementation
of harm reduction programs. PWID will benefit from dedi-
cated HIV prevention and treatment programs, particularly
care services that integrate ARTwith opioid substitution and
tuberculosis treatment [5, 11, 45].
Governments’ approach to drug users is often focused on
punishment and strategies to reduce drug supply. Not
enough effort has been focused on reducing demand.
Youth friendly services, such as education and information,
youth and community development services are employed
to greater extent in Western Europe, and to a lesser extent, in
Central and Eastern Europe and Central Asia. A large pro-
portion of young people, especially those who have started
injecting and are at risk of HIV, HCV, and other infectious
diseases, remain outside the reach of services. There is a
lack of comprehensive education approaches addressing
both drug consumption and sexual behaviors. Addressing
these issues and the health and social risks associated with
drug use in a non-judgmental, non-stigmatizing, and sup-
portive environment is essential. The risk environment, es-
pecially for youth is determined by individual, social and
structural factors. In Eastern Europe and Central Asia, this
vulnerability is exacerbated by stigmatization, politicization
and punitive attitudes of the government and of society.
These countries need to recognize that injection addiction
is a disease that is treatable.
The global goal of reducing the number of people who
use drugs who acquire HIV infection by 50 % by 2015 still
faces enormous challenges. In Eastern Europe and Central
Asia, most of new HIV infection in drug users occurs in
those regions that spend little on prevention programs.
Although funding for HIV prevention programs for people
who inject drugs has increased – between 2006–2007 and
2010–2011 in 18 countries for which data were available–
most of the increased funding was provided by international
donors, which accounted for 92 % of total HIV targeting
injecting drug users in 2010–2011. In most countries, do-
mestic public sector sources have yet to give priority to
funding programs to address the HIV-related needs of peo-
ple who inject drugs. A more vigorous approach is required
in Eastern Europe and Central Asia to meet the global goal
of halving the number of people who inject drugs who
acquire HIV infection by 2015.
Available evidence indicates that the world is far from
being on track to achieve the global target for people who
inject drugs. Substantially stronger commitment is urgently
needed to bring evidence-informed responses to scale. As
many countries fail to report data on HIV and people who
inject drugs, immediate steps are needed to improve the
reporting of sex-aggregated epidemiological and HIV ser-
vice coverage data for this population, with the aim of
ensuring reliable national estimates of the total number of
people who inject drugs. Countries that do not currently
address the needs of people who inject drugs in their na-
tional AIDS strategies should take immediate steps to rectify
this. Governments must urgently commit major new re-
sources to comprehensive evidence-informed prevention
programs for people who inject drugs and intensify efforts
to increase the scale of HIV testing, opioid substitution
therapy needle distribution and condom use.
China’s experience in the face of the HIV epidemic offers
valuable lessons. In 1989, the first outbreak of HIV was
reported in 146 heroin users in Yunnan province, which
borders Vietnam, Myanmar, and Laos [59]. The epidemic
spread to other regions borderingmajor drug trafficking routes
and by 1998, the epidemic had spread to all Chinese prov-
inces. Initial national strategies, which proved ineffective,
relied on containment and isolation of discovered cases as
well as barring HIV-infected foreigners and imported blood
products from entering China [60]. In the mid-1990s, a second
outbreak emerged in east-central China among commercial
blood plasma donors who were infected by contaminated
reinfusions of red blood cells [61]. In 2003, political commit-
ment accelerated following the rising of the new Hu Jintao
presidential administration and the severe acute respiratory
syndrome (SARS) epidemic, leading to implementation of
evidence-based polices, including NSPs, methadone mainte-
nance treatment programs, and subsidized ART programs
[59]. However, barriers to timely scale-up of programs includ-
ed inadequate structural and personnel resources, conflicts
between health and public security departments, and incon-
sistent policy enforcement. By the end of 2011, China had an
estimated PWLHA population of 780,000 and a majority of
infections were thought to have been transmitted by sexual
contact [22]. The number of newly reported cases has risen
annually. The proportion of newly reported cases resulting
from sexual transmission increased from 75.7 % in 2009 to
81.6 % in 2011.
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China’s experience offers an urgent lesson to other coun-
tries whose current HIV epidemics are primarily driven by
injecting drug use. High HIV prevalence among PWID
populations can translate to a rapidly spreading epidemic
in the general population by sexual transmission and
mother-to-child transmission. Addressing the HIV epidemic
among PWID populations can prevent untold numbers of
HIV infections and save considerable resources.
Conclusions
The new HIV infections among PWID occurring in Asia and
Eastern Europe account for a considerable proportion of the
total number of new HIV infections among PWID globally.
Though a few countries have taken initiative to implement
and to scale up harm reduction strategies, the overall cover-
age in these two regions is far below the minimum require-
ment to bring the HIV epidemic under control. The time to
act is now. Strong government commitment to controlling
the HIV epidemic among and from PWID, changing policy
approaches from punitive to therapeutic, and significantly
increasing domestic financial support for harm reduction are
critically important for success. The experience of China in
the last two decades offers crucial lessons for its neighbor-
ing countries in these regions. Asian and Eastern European
countries should increase cooperation in sharing experi-
ences to better understand how solutions can be tailored to
each nation’s unique situation. If countries work together
starting now, the millions of lives and billions of dollars lost
every year to opioid dependence can be avoided.
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